ASX

Markets to open higher, ASX up 1.3% on the back of CSL (ASX: CSL), National Australia Bank (ASX: NAB) profit crushed, ‘Nirvana’ for sharemarkets. The ASX 200 (ASX: XJO) delivered another strong day as it became more clear that Joe Biden would be the next President of the United States. Despite the election still being…

And still they keep coming – here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. As always, don’t let the impressive sexiness of the technology persuade you on its own that these stocks are headed for the stars. In each of the three cases presented here, previous investors…

Return of the A$ Corporate Hybrid Market Many of us who are old enough will remember the once-thriving ASX-listed corporate hybrid market as a constant feature of the pre-GFC Australian credit landscape, with the innovatively named Multiplex SITES, Fairfax PRESSES and Dexus RENTS securities (among others) offering returns and features to meet the risk appetites…

Here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts’ consensus target price: 14 cents (Thomson Reuters) You would not know it from the share price performance over the last few years, but Brisbane-based ImpediMed has put…

Generalising is a dark art. The moment one observes an apparent pattern, idiosyncratic data jumps out. Judging small-cap managers falls into this trap. Firstly, to the organisation. Those that are entirely dedicated to this sector can do well, yet are interspersed are some big shops with banal marketing that challenge this assumption. Boutique is not…

The launch early in February this year of Australia’s first unlisted fund to be quoted on the ASX, by Magellan group and its administrator, Mainstream, took a while to sink in, not helped by the dislocation caused by the pandemic crisis. But, as Australia at least, is preparing to get back to business at some…

ASX struggles higher, rates on hold, giant gold merger, US stocks fall The ASX 200 (ASX:XJO) struggled to a 0.3% gain on Tuesday, the energy, +2.3%, and materials sector, +1.1%, the key contributors. The biggest news was the ‘merger of equals’ between Australian gold miners Saracen Minerals (ASX:SAR) and Northern Star Mining (ASX:NST). The merger…

Another fintech is heading for the ASX screens, with online mortgage provider Lendi poised to push “go” on an initial public offering (IPO) that could see it list at a market capitalisation of between $500 million-$550 million. Lendi specialises in the home loan market: its software platform matches borrowers with more than 35 lenders. The…

4DMedical (4DX, $1.58)Market capitalisation: $418 millionThree-year total return: n/aAnalysts’ consensus target price: $1.70 (Thomson Reuters) Imaging company 4DMedical (4DX) surged on to the ASX screens in its August float, at a 100% “pop.” Issued in the prospectus at 73 cents, the shares opened for trade on August 7 at $1.47, and reached $1.70 in August…

We are pleased to speak with Luke Laretive of Seneca Financial Solutions this week. Luke Laretive must be one of the most prolific sharemarket writers in the market, filling LinkedIn with insightful weekly insights. Laretive offers a unique view of the industry having started in a full-service broking house before going out on his own…